Improved Screening Uptake Could Help Double Lung Cancer Survival by 2025
Between 60% and 65% of patients with lung cancer receive their diagnoses at stage III or IV, meaning that one-third are unaware of their disease when radical surgery, either alone or with adjuvant therapy, could be curative.
Although ads to promote tobacco products have been curtailed during the past few decades, cancer from using tobacco products still kills more than 8 million people each year, according to the World Health Organization.
Sotorasib Shows Early Activity Against KRAS G12C Mutant NSCLC
The first-in-class KRAS G12C inhibitor sotorasib has demonstrated early, deep, and durable responses in the treatment of advanced NSCLC with KRAS G12C mutations, according to results from the registrational phase II CodeBreaK 100 trial.
Nivolumab Boosted Survival in Relapsed Mesothelioma
Nivolumab significantly improved investigator-reported progression-free survival and overall survival compared with placebo in patients with relapsed malignant mesothelioma, according to preliminary results of the CONFIRM phase III trial presented during the Presidential Symposium.
Genetically Tailored Treatment Approach Did Not Improve Survival in Stage II-III NSCLC
Evaluation of mRNA expression of selected genes to tailor adjuvant chemotherapy did not improve survival outcomes in patients with resected stage II-III NSCLC, according to results of the ITACA study, presented during the Presidential Symposium.
If you require CME credits, please fill out the confirmation form that is available during or at the end of each session. You will only receive credits for the sessions for which you have completed the form. You can claim credits until March 30, 2021.
CME Certificates will be automatically sent on April 12, 2021 to all delegates who completed the confirmation forms.
A Certificate of Attendance will be sent to all registered non-physicians immediately following the conference.